anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
As Vitamin E comprises a mixture of tocopherol and tocotrienol isomers, presently most emulsifying formulations targets the former, especially α-tocopherol. We disclose a formulation targeting tocotrienols and derivatives thereof for self-emulsifying drug delivery system. The formulation comprises 2 non-ionic surfactants acting as emulsifiers and a glyceride acting as oil carrier admixed with tocotrienol. Specifically, the emulsifiers are sorbitan monolaurate and polyoxyethylene sorbitan 20 monooleate in the range of 10% to 60% by weight, preferably 15% to 45% and in a ratio range of 1:1 to 1:20, preferably 1:2 to 1:8. Tocotrienol-rich source of Vitamin E in the form of fat-soluble compound is provided in a range of 5% to 60%, preferably 10% to 50% by weight of the formulation. The oil carrier may be limited up to 85% by the formulation’s weight, preferably between 6% to 56%, and may be chosen from glycerol trioleate, triglycerides, oleic acid, palmitic acid, stearic acid and mixtures thereof. The formulation may be made into powder, tablet or capsule for administration as a dietary supplement.
PURPOSE: To obtain a cell adhesion inhibitor containing a glucide compound as an active component and active to suppress the adhesion of immunocytes participating in the suppression of the infiltration of inflammatory cells or the recognition of antigen. CONSTITUTION: A glucide compound of the formula (one of R<1> and R<2> is H and the other is a lower alkoxy, OH, etc., R<3> to R<5> are each (CO)R<6> or H; R<6> is an alkyl, furoyl, etc.) or its solvated compound is used as an active component. The compound of the formula is useful as an anti-inflammatory agent for acute and chronic inflammatory diseases (rheumatism, gonarthrosis, etc.), an immunotherapeutic agent for autoimmune diseases, an anti-allergic agent, an antiasthmatic agent and a cancer metastasis suppressing agent and is effective for the prevention and treatment of ischemic diseases such as myocardial infarction, arteriovenous obstruction and cerebral infarction, nephritis fulminant hepatitis, transplantation immunity rejection, etc.  It can be formed in the form of oral drug or parenteral drug such as injection, suppository, percutaneous agent, etc., by properly compounding conventional carriers, diluents, additives, etc. It is administered at a daily rate of 0.1-1,000mg for adult in 1-4 divided doses in the case of oral administration.
Immunometabolism is a fascinating field of research that investigates the interactions between metabolic processes and the immune response. This intricate connection plays a pivotal role in regulating inflammatory reactions and consequently exerts a significant impact on the course of sepsis. The proinflammatory response during an immune reaction is closely tied to a high energy demand in immune cells. As a result, proinflammatory immune cells rapidly require substantial amounts of energy in the form of ATP, necessitating a fundamental and swift shift in their metabolism, i.e., their means of generating energy. This entails a marked increase in glycolysis within the proinflammatory response, thereby promptly meeting the energy requirements and providing essential metabolic building blocks for the biosynthesis of macromolecules. Alongside glycolysis, there is heightened activity in the pentose phosphate pathway (PPP). The PPP significantly contributes to NADPH production within the cell, thus maintaining redox equilibrium. Elevated PPP activity consequently leads to an increased NADPH level, resulting in enhanced production of reactive oxygen species (ROS) and nitric oxide (NO). While these molecules are crucial for pathogen elimination, an excess can also induce tissue damage. Simultaneously, there are dual interruptions in the citric acid cycle. In the cellular resting state, the citric acid cycle acts as a sort of "universal processor", where metabolic byproducts of glycolysis, fatty acid breakdown, and amino acid degradation are initially transformed into NADH and FADH2, subsequently yielding ATP. While the citric acid cycle and its connected oxidative phosphorylation predominantly generate energy at rest, it becomes downregulated in the proinflammatory phase of sepsis. The two interruptions lead to an accumulation of citrate and succinate within cells, reflecting mitochondrial dysfunction. Additionally, the significantly heightened glycolysis through fermentation yields lactate, a pivotal metabolite for sepsis diagnosis and prognosis. Conversely, cells in an anti-inflammatory state revert to a metabolic profile akin to the resting state: Glycolysis is attenuated, PPP is suppressed, and the citric acid cycle is reactivated. Of particular interest is that not only does the immune reaction influence metabolic pathways, but this connection also operates in reverse. Thus, modulation of metabolic pathways also modulates the immunity of the corresponding cell and thereby the state of the immune system itself. This could potentially serve as an intriguing avenue in sepsis therapy.
After acute myocardial infarction (AMI), intercellular communication is crucial for maintaining cardiac homeostasis and patient survival. Exosomes secreted by cardiomyocytes serve as carriers for transporting microRNA(miRNAs), participating in intercellular signaling and the regulation of cardiac function. This study aims to investigate the role of exosomal microRNA-30a(miR-30a) during AMI and its underlying mechanisms. AMI was induced by permanent ligation of the left anterior descending (LAD) artery in C57BL/6 mice. The expression of miR-30a in mice was respectively enhanced and inhibited by administering agomiR-30a and antagomiR-30a. Using HL-1 cardiomyocytes and RAW264.7 macrophages for in vitro experiments, HL-1 cardiomyocytes were cultured under hypoxic conditions to induce ischemic injury. Following isolation and injection of exosomals, a variety of validation methods were utilized to assess the expression of miR-30a, and investigate the effects of enriched exosomal miR-30a on the state of cardiomyocytes. After AMI, the level of exosomal miR-30a in the serum of mice significantly increased and was highly enriched in cardiac tissue. Cardiomyocytes treated with agomiR-30a and miR-30a-enriched exosomes exhibited inhibition of cell autophagy, increased cell apoptosis, mice showed an larger myocardial infarct area and poorer cardiac function. Exosomes released from hypoxic cardiomyocytes transferred miR-30a to cardiac resident macrophages, promoting the polarization into pro-inflammatory M1 macrophages. In conclusion, murine exosomal miR-30a exacerbates cardiac dysfunction post-AMI by disrupting the autophagy-apoptosis balance in cardiomyocytes and polarizing cardiac resident macrophages into pro-inflammatory M1 macrophages. Modulating the expression of miR-30a may reduce cardiac damage following AMI, and targeting exosomal miR-30a could be a potential therapeutic approach for AMI.
Blast mTBI (concussed) participants will be administered the VOMS after concussive blast event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
The present invention discloses SEQ? ID? The nucleotide sequence shown in NO.1, and also discloses a recombinant virus containing the nucleotide sequence and application thereof. The recombinant lentivirus can inhibit a drug-resistant protein Pgp and a drug-resistant related gene H? I? The expression of the F-1 alpha can also reduce the pumping rate of the medicine, can reverse the drug resistance of the intractable epilepsy, can be used together with other medicines for treating the epilepsy, treats the intractable epilepsy and has good clinical application prospect.
Patients receive doxepin hydrochloride oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm II on day 2.
Alkaline burns to the cornea lead to loss of corneal transparency, which is essential for normal vision. We used a rat corneal alkaline burn model to investigate the effect of ophthalmic trimebutine solution on healing wounds caused by alkaline burns. Trimebutine, an inhibitor of the high-mobility group box 1-receptor for advanced glycation end products, when topically applied to the burned cornea, suppressed macrophage infiltration in the early phase and neutrophil infiltration in the late phase at the wound site. It also inhibited neovascularization and myofibroblast development in the late phase. Furthermore, trimebutine effectively inhibited interleukin-1β expression in the injured cornea. It reduced scar formation by decreasing the expression of type III collagen. These findings suggest that trimebutine may represent a novel therapeutic strategy for corneal wounds, not only through its anti-inflammatory effects but also by preventing neovascularization.
Cardiovascular disease (CVD) is the leading killer of Americans, accounting for more than 800,000 deaths each year. A vital step in reducing the number of heart disease-related deaths in the U.S. is to identify those at probable risk. The Clinical Chemistry Branch (CCB) in the Division of Laboratory Sciences (DLS) at the Centers for Disease Control and Prevention (CDC) has developed advanced analytical methods for assessing the risk for lipid metabolism related diseases, including CVD. This comprehensive analytical method measures levels of protein and lipid constituents of lipoprotein size and density classes (e.g. high-density lipoprotein (HDL), low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL)) in blood. The analytical method uses asymmetric flow-field flow fractionation (AF4) to separate lipoprotein classes (HDL, LDL, VLDL) in serum or plasma into size fractions, and in each fraction quantifies over 50 CVD-linked biomarkers by isotope dilution tandem mass spectrometry. The CCB plans to apply the measurement of this wide array of biomarkers in future epidemiologic investigations of CVD. These studies have the potential to expand the number of diagnostically relevant CVD risk factors that currently are limited to cholesterol and triglyceride measurements.

However, there is limited information about how the CVD-linked biomarkers measured with the CCB's method are affected by blood collection conditions and the fasting/non-fasting state of individuals. Furthermore, lipid metabolism is very dynamic and the absolute levels of biomarkers are strongly affected by each individual's diet, lifestyle, gender, age, and physiology. Thus, assessing biomarkers related to lipid metabolism is most effective in a pre- and post-test comparison (i.e. fasting vs. after a test meal) with controlled lipid and carbohydrate content.

The study involves three different meal challenges on three separate days with approximately two weeks in between. The first meal challenge will involve the consumption of a standardized mixture of dietary fats (lipid challenge), the second meal challenge will be a sugar sweetened beverage (glucose challenge) and the third meal challenge will be a nutrition shake (mixed meal challenge). At each of the three visits, each individual will provide both venous and finger-prick blood samples and a urine sample before consuming the test meal (in a fasting state) and 6 additional venous and finger-prick blood samples post-meal at described intervals. Each study visit will last approximately 8 hours.
PROBLEM TO BE SOLVED: To obtain a composition excellent in conditioning effect, effective for protecting hair from being damaged by ultraviolet light rays, containing a quaternary ammonium salt type surfactant, an oily substance and a water-soluble ultraviolet light absorber. SOLUTION: This hair conditioner composition contains 0.01-10wt.% of a quaternary ammonium salt type surfactant (e.g. stearyltrimethylammonium chloride), 0.5-10wt.% of an oily substance (e.g. silicone oil) and 0.05-5wt.% of a water-soluble ultraviolet light absorber (e.g. 5-benzoyl-4-hydroxy-2- methoxybenzenesulfonic acid). The composition comprises further a nonionic surfactant by blending the nonionic surfactant with the cationic surfactant and the amount of the nonionic surfactant is 0.5-5wt.%. The composition is blended with an amphoteric surfactant. The composition is further mixed with a cationic polymer and a polysiloxane preferably in terms of combing properties and touch. The composition is preferably used as an aqueous emulsion and a dispersion. Further, the aqueous emulsion and the dispersion can be used as an aerosol or a foamy aerosol by using an inert gas.
AIM OF THE STUDY: Neonatal enterostomy is a known risk for growth failure. We hypothesized that episodes of inflammation may drive a catabolic state, exploring this by assessing serum biochemistry alongside growth trajectory in enterostomy patients.
METHODS: A retrospective analysis of infants with histologically confirmed NEC from 01/2012-07/2021 in a tertiary neonatal surgical centre was performed. Change in weight-for-age Z-score (ΔZ) between stoma formation and closure was calculated. Serum CRP (C-reactive protein), urea, and creatinine levels were recorded and duration of elevated levels calculated as Area Under Curve (AUC). We examined for trends of serum levels rising together using intersecting moving averages. Spearman's correlation analysis was performed, while multivariable linear regression examined factors associated with ΔZ.
RESULTS: 79 neonates were included. At stoma formation, median Z-score was -1.42 [range -4.73, +1.3]. Sixty-two patients (78 %) had a fall in Z-score during their time with a stoma, 16 (20 %) had a ΔZ less than -2. Urea AUC was significantly univariably correlated with ΔZ and remained statistically significant in a multivariable model (Exp(B) x 100 = -0.57[-1, -0.09]; p = 0.022). The number of biomarker peaks correlated significantly with ΔZ for urea (r = -0.25; p = 0.025) and CRP (r = -0.35; p = 0.0017) but not Creatinine (r = -0.21; p = 0.066). Analysing the number of peaks of any combination of variables coinciding was consistently significantly correlated negatively with ΔZ (r = -0.29 to -0.27; p ≤ 0.016 for all).
CONCLUSION: Our data shows that infants who were more severely affected by growth failure had more frequent and severe uremia while they had a stoma (suggesting a catabolic state). Disturbances in urea were commonly associated with CRP, suggesting that inflammation is a significant factor in growth failure in these infants. These findings promote aggressive management of sepsis in these infants, as well as suggesting an earlier closure of stoma to minimise their "at-risk"' period.
A device for use in hair treatment (e.g. highlighting) comprises a clip which may be conveniently manufactured in plastic and comprises two flat plates (1 and 2) of rectangular shape being joined by an integral hinge (3), for example of flexible plastic. The plates may be closed together by flexure about the hinge (3) and fastened in the closed position by means of a latch (4). The inner faces of each plate have an applied strip of a retentive or absorbent resilient material such as rubber or plastic foam or plastic wool (5). These absorbent strips may be secured for example by projecting spikes (6) which penetrate the strip, or may be permanently or releasably bonded to the surfaces of the plates. Tinting cream may be applied to one or both of the absorbent strips and selected tufts of hair are each held in a cream coated clip; the clips are easily placed and fastened using one hand only, allowing the other hand to keep a secure grip on the tuft of hair. <IMAGE>
The term “medical cannabis” and “medical marijuana” existed long before any codifying of law. They were around before industry began and the words actually had meaning. Medical cannabis means sensimilla, and sensimilla is a latin word meaning “without seed.” The reason sensimilla is preferred for medicine is simple. Cannabis plants are highly photo-sensitive. This means the plant's entire life cycle must be controlled with light to efficiently and effectively produce medicine. When done properly you will have a vegetative photo-period and a flower photo-period, each being different in duration, intensity, and color of lighting. Working like this allows you to keep a “mother plant” theoretically indefinitely. This allows you to increase plant potency over time and gives you a source for clones. Clones can be developed directly beside the mother until ready to flower. Establishing a mother plant and taking clones allows for a few things. First, you now have a reliable source of female cannabis plants and no seeds are required to be germinated. Second, potency goes up the longer the mother is in the vegetative state. Third, if there are any abnormalities it is easy to spot. Training yourself to cultivate in this manner will make it really easy to identify when “somethings wrong”, and with cannabis something wrong can turn catastrophic quickly. When the female clone has matured and is ready for flowering they are moved away from the mother. They are provided with a different color of light, as well as duration of light and nutrients. When a cannabis plant is flowering in this manner and no male plants are present, and no pollination occurs, it is now in prime condition to provide our medicine, in the form of its resin. In nature, the resin is what the plant uses to entice pollination. If unpollinated, a cannabis plant will freely flow its resin until harvest. If pollinated, it begins to shut down resin flow because it no longer needs to be pollinated. This is when the plant begins to put its energy into seed production and inhibits our medicine. It is particularly this reason why it is imperative for “medical cannabis” to meet the standard of sensimilla.
FIELD: veterinary biology and immunology. SUBSTANCE: the present innovation deals with manufacturing and application of biological preparations for vaccination in animals. The suggested vaccine includes protective antigen of vaccine strain 55 VNIIVV&M at concentration of 17,5±2,5 immunizing doses and alive spores of vaccine strain STI-1 at concentration of 2,5±0,3•10 7 /ml physiological solution. This vaccine is safe and provides tense antitoxic and antimicrobial immunity against anthrax. This innovation could be applied for specific prophylaxis of anthrax in animals. EFFECT: higher efficiency. 6 tbl
The purpose of this study is to understand how a healthy diet is related to thinking ability and heart health. Participants will be asked to consume a microwaveable study meal or prepackaged smoothie every day for 12 weeks. These meals will be delivered to participant homes using Daily Harvest meal delivery service. The study meals and smoothies will follow either a dietary pattern thought to improve brain and heart health (MIND), or a control diet, and will include foods commonly found in grocery stores. Participants will not know which diet they are assigned to (active or control). Participants will also be asked to follow simple dietary guidance on a healthy diet in addition to the meals provided. Participants will complete a series of online forms or surveys. Additionally, participants will come to 4 in-person laboratory visits to complete several computer-based tests of memory and attention while wearing an EEG cap. Participants will also be asked to complete an eye test, a heart rate and blood pressure assessment, a bone and body scan called DXA, and a blood draw at the beginning of the study and again at the end of the 12-week diet period.
Disclosed are a Chinese medicinal composition for treating obesity and a preparation method thereof. The Chinese medicinal composition is prepared by following raw materials: astragalus root 25-275g, asiabell or beach silvertop root 10-190g, bighead atractylodes rhizome or yam 10-190g, hyacinth bean 25-575g, magnolia vine fruit 5-95g, notoginseng or red sage root or chuanxiong rhizome 0-190g, epimedium 0-190g. Also disclosed is a method for preparing the capsule of the Chinese medicinal composition. The invention can reduce weight without harming health of the people. It is primarily suitable for simple obesity and complications thereof. For treating simple obesity and complications thereof caused by spleen-qi deficiency, kidney-yang deficiency, stomach heat and insufficiency of qi and yin, the total effective rate reaches 90% in clinical practice. The toxicity test proves that the composition is safe.
FIELD: medicine, perfume and cosmetic industry. SUBSTANCE: invention relates to massage and cosmetic creams based on natural raw. Cream has water-soluble and lipid extracts of sludge sulfide muds, lanolin, Vaseline, water, p-hydroxybenzoic acid methyl ester taken in the definite ratio of components. Invention provides the development of effective cosmetic massage cream based on natural raw that is impracticable for balneology. EFFECT: enhanced effectiveness of cream. 2 cl, 5 ex
Nimotuzumab 150 mg /mq/d as iv weekly and Vinorelbine 20 mg/mq/d weekly, in week 1-12 (Induction phase).If not progression Nimotuzumab 150 mg/m2 as iv and Vinorelbine 25 mg/m²/d as iv until progression or maximum at week 108; in case of non-progressive disease re-irradiation 1 for a total of 19.8 Gy from week 26 to week 28; in case of non-progressive disease: re-irradiation 2 for a total of 19.8 Gy from week 46 to week 48. Irradiation will be scheduled to begin in the 3rd week after starting the nimotuzumab and vinorelbine treatment. For the first course, a total dose of 36 Gy will be delivered, in 1.8 Gy daily fractions 5 days a week.
This study is a non-blinded randomized controlled trial and a concurrent Health Economic. The study examines the effect on wound healing using NPWT compared with conventional wound treatment in women, who experience spontaneous dehiscence or where a surgeon deliberately opens the wound after Caesarean Section (CS).

Women, who have given informed consent, will be randomized to either intervention or control group via a computer-generated randomization program. It is not possible to blind either participants or therapists. The analysis will be carried out on an intention to treat basis.

Women with post-CS wound infection will be hospitalized and the wound will be reopened and cleaned under general anaesthesia. In the intervention group women will be treated with NPWT. The change of wound dressing on the second day takes place in the obstetrical or plastic surgery ward. On the fourth day, the NPWT material will be removed and the wound evaluated before re-suturing. In the control group the wound will be treated with a hydrofiber or alginate dressing. Changes of wound dressing will take place on the second and fourth days as in the intervention group. In both groups, when the wound is evaluated on the second and fourth day, it will be described and measured (depth, width, length). After four days of treatment, the wound will be re-sutured in both groups. It is expected that some wounds are not suitable for re-suturing on the fourth day. If a woman does not want to participate, she will receive the conventional treatment, which corresponds to the treatment in the control group. Women, who do not wish to participate, will be asked for permission to use their data in the analysis.